LOS ANGELES--(BUSINESS WIRE)--Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that data from various Phase I and Phase II clinical trials of Cougar’s lead drug candidate CB7630 (abiraterone acetate) will be presented during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will take place May 30th through June 3rd in Chicago. Details from both the oral presentations and the poster presentation are as follows:
